S100B, affinity purified antibody, goat, 100 ug.
- Known as:
- S100B, antigenic enriched (anti-), caprine, 100 ug.
- Catalog number:
- GT15160-100
- Product Quantity:
- 1
- Category:
- -
- Supplier:
- Neuromi
- Gene target:
- S100B affinity purified antibody goat 100 .
Related genes to: S100B, affinity purified antibody, goat, 100 ug.
- Gene:
- S100B NIH gene
- Name:
- S100 calcium binding protein B
- Previous symbol:
- -
- Synonyms:
- S100beta
- Chromosome:
- 21q22.3
- Locus Type:
- gene with protein product
- Date approved:
- 1988-06-27
- Date modifiied:
- 2014-11-18
Related products to: S100B, affinity purified antibody, goat, 100 ug.
Related articles to: S100B, affinity purified antibody, goat, 100 ug.
- : The aim of this study was to comprehensively analyze the relationships within a multimodal biomarker panel, including endothelial function indicators, markers of systemic inflammation and myocardial stress, metabolic homeostasis parameters, and an indicator of microstructural damage to nerve tissue in CAD patients with or without type D personality. : This exploratory, cross-sectional, observational study included 72 patients with coronary artery disease. All patients underwent psychological testing (evaluation of type D personality and determination of depression and anxiety levels) and biomarker measurements. The multimodal biomarker panel included measurements of metabolic homeostasis parameters (glucose, total cholesterol, creatinine, insulin, 1,5-anhydroglucitol), markers of systemic inflammation (CRP, IL-6), myocardial stress (NTproBNP), endothelial function parameters (eNOS, EDN1, ADMA, VEGF), and an indicator of microstructural damage to nerve tissue (S100B protein). : Biomarker levels revealed no statistically significant differences between the groups with and without personality type D. In personality type D, a direct correlation was found between the level of the brain tissue damage marker S100B and eNOS concentration (R = 0.578; = 0.006), which was not observed in non-type D. In patients with personality type D, a significant inverse correlation was confirmed between ADMA and creatinine levels (R = -0.524; = 0.015). In individuals with non-type D personality, a direct correlation was established between total cholesterol levels and VEGF (R = 0.342; = 0.014). : In patients with coronary heart disease, psychological distress (type D) is associated not with an isolated change in biomarker concentrations but with a transformation of the entire structure of their relationships. Personality type D is characterized by a transition from the physiological autonomy of systems to the formation of pathogenetic relationships between them, indicating a decrease in adaptive reserve. - Source: PubMed
Publication date: 2026/07/03
Sumin Alexey NZagorskaya Natalia NBezdenezhnykh Natalia AShcheglova Anna VBryukhanov Yaroslav ISinitskaya Anna V - Oral health plays a crucial role in maintaining cognitive functions, reflecting a complex interplay between the oral cavity and brain health. Emerging evidence indicates that various oral disease-associated protein molecules are implicated in the pathogenesis of diverse neuronal disorders, including neurodegenerative diseases. This review comprehensively summarizes oral disease-related protein molecules implicated in several neuronal disorders, including Alzheimer's disease, Parkinson's disease, neurodegeneration, neuroinflammation, dementia, cognitive decline, and brain fog in two different contexts. Firstly, it describes protein molecules under the classical oral disease condition [Aβ42, total-Tau, phosphorylated-Tau, α-synuclein, DJ-1, lactoferrin, MMP-2/8/9, IL-6, IL-1β, TNF-α, CRP, S100A8, S100A9, S100B, RAGE, LCN2, cathepsin B/L, HSP70/90, NfL, CXCL2/8, C3/4, defensins (α and β), and lysozyme]. Secondly, in COVID-19 context [ACE2, TMPRSS2, furin-1, NRP1, spike, T1R, and T2R]. It explores oral proteins implicated in neuronal disorders, highlighting their roles in activating inflammatory pathways, contributing to memory impairment, and mediating taste dysfunction in the context of COVID-19. Furthermore, the review delineates the mechanisms underlying the oral-brain axis, highlighting the roles of systemic inflammation, microbial interactions, and blood-brain barrier dysfunction in mediating these effects. It also highlights the innovative diagnostic potential of oral disease-associated proteins as non-invasive biomarkers for early detection and monitoring of neuronal disorders in both classical and COVID-19 contexts. In addition, the emerging therapeutic significance of these proteins is discussed, emphasizing their potential as molecular targets for the prevention and treatment of neurological diseases. Understanding oral disease-associated protein molecules provides novel insights into early diagnosis and progression of neuronal disorders. - Source: PubMed
Publication date: 2026/07/14
Murugan Avaniyapuram Kannan - Reliable biomarkers that capture central nervous system (CNS) processes during the earliest stages of psychosis are critically needed to improve early treatment and response monitoring. Brain-derived extracellular vesicles (BDEVs) that traverse the blood-brain barrier (BBB) can be isolated from peripheral blood, thereby offering a novel and minimally invasive approach to quantify CNS molecular biomarkers. We hypothesized that BDEV abundance and BDEV neuroinflammatory and neurotrophic protein cargo would differ between individuals with first-episode psychosis (FEP) and healthy controls (HCs), reflecting altered neuroinflammatory signalling and extracellular biology associated with psychosis and clinical outcomes. In a cohort of untreated individuals with FEP (n = 57) and HCs (n = 28), BDEVs were isolated from serum. Luminex assays quantified concentrations of brain-derived neurotrophic factor (BDNF), S100 calcium-binding protein B (S100B), and C-reactive protein (CRP) in BDEVs and serum. A subset of FEP participants (n = 34) subsequently completed four weeks of antipsychotic treatment. Group differences in BDEV characteristics and protein measures, as well as their associations with case-control status, baseline symptom severtity, and four-week symptom change, were examined. FEP participants showed a trend toward higher BDEV concentration than HCs (median 14.0 × 10 versus 10.2 × 10 particles/mL, p = 0.052), and higher baseline BDEV concentrations were significantly associated with more severe pretreatment symptoms (β = 4.09 × 10, p = 0.003) and greater symptom improvement after four-week antipsychotic treatment (β = 3.29 × 10, p = 0.029). Within BDEVs, BDNF (β = -1.05; p = 0.0018) and CRP (β = -0.84; p = 0.002) were significantly reduced in FEP vs HC, with a trend toward lower S100B level (β = -0.57; p = 0.061). In contrast, serum protein levels showed no case-control differences and did not correlate with corresponding BDEV protein levels. Lower baseline BDEV BDNF, S100B, and CRP were associated with greater therapeutic response among males. BDEVs offer a minimally invasive window into CNS-enriched biology in early psychosis. BDEV abundance and neuroinflammatory and neurotrophic cargo concentrations show associations with illness severity and sex-specific treatment response not detectable in serum, supporting their potential as biomarkers for early pathophysiology and treatment response in FEP. - Source: PubMed
Publication date: 2026/07/12
Zhang LusiLee Adam MMaxim Zia LMunirathinam ManjulaLarsen Bart SGeorgieff Michael KKeedy Sarah KReilly James LSweeney John ATran Phu VBishop Jeffrey R - Pain in Parkinson's disease (PD) is common and significantly reduces quality of life, yet it is often poorly managed. As current treatments have limitations, acupuncture may offer a non-pharmacological option. This trial aims to evaluate the efficacy and safety of acupuncture versus sham acupuncture for pain in PD. - Source: PubMed
Publication date: 2026/06/29
Wu YixuanZhang FanXiao LiangmanWang YutingLin ShuminWu ShunanLiu XinZhuang Lixing - With more than 300,000 new cases diagnosed in 2022 and a projected rise in incidence until the year 2040, malignant melanoma remains a major global health challenge. Of note, immunotherapy has substantially improved survival outcomes, even in advanced stages. Nevertheless, reliable biomarkers for early relapse detection, risk stratification, and treatment monitoring remain an unmet clinical need. Conventional surveillance tools, including imaging, lactate dehydrogenase (LDH), and S100B, are limited by their sensitivity and specificity, particularly in patients with low tumor burden. The use of liquid biopsy, the analysis of body fluids such as blood, with its wide range of analytes and highly sensitive analysis methods, may represent a novel strategy to overcome the limitations of conventional biomarkers. In particular, the analysis of circulating cell-free nucleic acids from the tumor released to the blood, referred to as circulating tumor DNA (ctDNA), has emerged as a minimally invasive approach capable of capturing tumor-derived molecular information from plasma in solid tumors. ctDNA holds promise as a tool for the detection of minimal residual disease (MRD), early relapse, clonal evolution, and actionable genomic alterations. Technological advances have expanded ctDNA applications from single-mutation assays to comprehensive personalized NGS strategies and multi-modal approaches incorporating methylation profiling and fragmentomics. Clinical studies increasingly demonstrate that ctDNA detection and ctDNA dynamics provide prognostic and potentially predictive information across both (neo)adjuvant and advanced melanoma settings. In this review, we summarize the current methodological approaches and clinical evidence supporting ctDNA as a biomarker for prognosis, risk stratification, and therapy monitoring in melanoma. - Source: PubMed
Publication date: 2026/07/03
Heidrich IsabelUrhahn SarahGebhardt ChristofferSmit Daniel JPantel Klaus